Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.
Cardior Pharmaceuticals GmbH has published results of preclinical in vivo studies in Nature Communications showing that its lead compound, CDR132L, can significantly improve the functioning of pathologically altered hearts.
How to increase the social benefit of European research funding? Members of the ASTP’s National Associations’ Advisory Committee (NAAC) recently met representatives of the European Commission (EC) in Brussels to discuss this question.